Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MURTAZA NAJMUDDIN BHURIWALA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1730142068
CMS profile
124523
Location
TOMBALL, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$7,244.64

138 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $4,895.00 6
Food and Beverage $2,249.69 131
Education $99.95 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MURTAZA NAJMUDDIN BHURIWALA

NPI 1730142068 · CMS profile ID 124523

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

TOMBALL, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730142068?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MURTAZA NAJMUDDIN BHURIWALA, NPI 1730142068, CMS profile ID 124523. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730142068?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MURTAZA NAJMUDDIN BHURIWALA, NPI 1730142068, CMS profile ID 124523. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730142068?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MURTAZA NAJMUDDIN BHURIWALA, NPI 1730142068, CMS profile ID 124523, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1730142068?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

138 matching records · $7,244.64 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 138 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–138 of 138.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $1,665.0003/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830073135 CMS
TOLMAR Pharmaceuticals, Inc. $11.8003/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836489019 CMS
Celgene Corporation $13.4103/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783733615 CMS
Celgene Corporation $0.2403/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783733617 CMS
Astellas Pharma US Inc $14.7203/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821262239 CMS
Merck Sharp & Dohme Corporation $15.7303/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848431315 CMS
Helsinn Therapeutics (U.S.), Inc. $20.3103/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819745855 CMS
Novartis Pharmaceuticals Corporation $23.3303/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812609963 CMS
Novartis Pharmaceuticals Corporation $9.5903/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812609957 CMS
Janssen Biotech, Inc. $15.7503/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788615899 CMS
Seagen Inc. $12.7103/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832159285 CMS
Merck Sharp & Dohme Corporation $11.9002/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848431911 CMS
Celgene Corporation $0.6502/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783733611 CMS
Celgene Corporation $12.9502/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783733613 CMS
GlaxoSmithKline, LLC. $14.0902/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802974121 CMS
Astellas Pharma US Inc $14.2202/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821262235 CMS
Amgen Inc. $14.2402/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826536777 CMS
Ipsen Biopharmaceuticals, Inc $18.4302/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841912771 CMS
MorphoSys, US Inc. $24.3502/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854736499 CMS
Karyopharm Therapeutics Inc. $17.4302/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845787539 CMS
Pharmacyclics LLC, An AbbVie Company $19.8102/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781008333 CMS
Coherus Biosciences Inc. $20.6501/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855105659 CMS
Amgen Inc. $17.4501/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825643821 CMS
Daiichi Sankyo Inc. $16.4301/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836244975 CMS
Taiho Oncology, Inc. $16.8201/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843384641 CMS
GlaxoSmithKline, LLC. $1.2101/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801673215 CMS
GlaxoSmithKline, LLC. $19.8101/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802316925 CMS
PUMA BIOTECHNOLOGY, INC. $22.0801/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834090701 CMS
Amgen Inc. $20.6001/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825643825 CMS
Seagen Inc. $14.2901/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832159245 CMS
Acceleron Pharma, Inc. $23.3701/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843318967 CMS
Epizyme, Inc., $13.8801/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832338239 CMS
Ipsen Biopharmaceuticals, Inc $18.3401/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841904461 CMS
BeiGene USA, Inc. $23.7401/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846698901 CMS
GlaxoSmithKline, LLC. $1,650.0001/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801669701 CMS
MorphoSys, US Inc. $15.2201/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854736493 CMS
Pharmacosmos Therapeutics Inc. $11.1301/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842719369 CMS
Pharmacosmos Therapeutics Inc. $11.1301/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842719593 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $11,026.43 123
PY2020 $4,494.10 104
PY2021 $7,244.64 138
PY2022 $4,902.12 160
PY2023 $3,914.62 203
PY2024 $8,661.33 180
PY2025 $9,550.15 184

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $241,507.08 35
PY2024 Principal investigator $64,345.11 8
PY2023 Principal investigator $51,752.20 4
PY2022 Principal investigator $115,328.39 14
PY2021 Principal investigator $35,983.00 14
PY2020 Principal investigator $45,114.44 9
PY2019 Principal investigator $114,947.11 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $7,499.70 11/04/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202520523
Principal investigator 1 ABBVIE INC. $7,307.30 10/21/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202517543
Principal investigator 1 ABBVIE INC. $6,385.50 10/21/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202517569
Principal investigator 1 ABBVIE INC. $6,385.50 10/21/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202517571
Principal investigator 1 ABBVIE INC. $7,307.30 10/21/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202517573
Principal investigator 1 ABBVIE INC. $6,367.95 10/09/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202514825
Principal investigator 1 ABBVIE INC. $4,084.60 10/09/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202514831
Principal investigator 1 ABBVIE INC. $1,431.00 10/09/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202515021
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,587.50 09/18/2025 Non-covered Recipient Entity
WALDRON MEDICAL RESEARCH & DEVELOPMENT LLC
C16038 (SWITCH) An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) No dispute reported 06/30/2026 1223285686
Principal investigator 1 ABBVIE INC. $1,967.53 09/04/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202508832
Principal investigator 1 ABBVIE INC. $9,061.00 09/03/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202507375
Principal investigator 1 ABBVIE INC. $405.81 08/06/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202502903
Principal investigator 1 ABBVIE INC. $4,864.60 08/05/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202501628
Principal investigator 1 ABBVIE INC. $1,378.00 07/10/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202497826
Principal investigator 1 ABBVIE INC. $8,275.50 07/09/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202497582
Principal investigator 1 ABBVIE INC. $5,682.30 07/09/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202497586
Principal investigator 1 ABBVIE INC. $2,523.30 07/08/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202497092
Principal investigator 1 ABBVIE INC. $5,370.30 07/02/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202494403
Principal investigator 1 ABBVIE INC. $11,573.52 06/03/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202489313
Principal investigator 1 ABBVIE INC. $5,823.90 06/03/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202489315
Principal investigator 1 ABBVIE INC. $7,880.60 06/03/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202489317
Principal investigator 1 ABBVIE INC. $2,800.00 05/22/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202485811
Principal investigator 1 ABBVIE INC. $10,077.14 05/07/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202482911
Principal investigator 1 ABBVIE INC. $11,367.00 05/07/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202482913
Principal investigator 1 ABBVIE INC. $12,313.35 04/16/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202477014
Principal investigator 1 ABBVIE INC. $10,818.60 04/16/2025 Non-covered Recipient Entity
MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202477036
Principal investigator 1 ABBVIE INC. $6,857.70 04/03/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202472970
Principal investigator 1 ABBVIE INC. $22,275.00 04/03/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202472973
Principal investigator 1 ABBVIE INC. $3,500.00 03/27/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202466977
Principal investigator 1 ABBVIE INC. $11,799.00 03/27/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202466991
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $944.62 03/11/2025 Non-covered Recipient Entity
WALDRON MEDICAL RESEARCH & DEVELOPMENT LLC
AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (IRD) IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY RECEIVING A BORTEZOMIB-BASED INDUCTION REGIMEN (US MM-6) No dispute reported 06/30/2026 1223276177
Principal investigator 1 ABBVIE INC. $12,625.20 03/07/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
M24-977 - A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202461957
Principal investigator 1 ABBVIE INC. $4,128.41 03/07/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202461960
Principal investigator 1 ABBVIE INC. $3,500.00 02/26/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
M24-977 - A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202453984
Principal investigator 1 ABBVIE INC. $14,338.35 02/26/2025 Non-covered Recipient Entity
MILLENIUM RESEARCH & CLINCAL
M24-977 - A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202453988